Ahead of ASCO, BMS' Opdivo leads Merck's Keytruda in U.S. sales—but not for long, analyst predicts

With all eyes on cancer treatments this weekend—in particular, immuno-oncology treatments— at the American Society of Clinical Oncology (ASCO) annual meeting, Bristol Myers Squibb’s Opdivo still leads the pack in terms of U.S. sales. But analysts don’t expect that lead to last long.